Ultragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($2.23), $0.16 worse than the analyst estimate of ($2.07). Revenue for the quarter came in at $98.1 million versus the consensus estimate of $109.79 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.